Vaderis Therapeutics
Develops an oral AKT inhibitor for hereditary hemorrhagic telangiectasia
$152MSeries B
Role not disclosedEL
EQT Life Sciences
Activity from announced rounds
Activity in this selectionSeries B
- Rounds participated in
- 4
- Confirmed lead rounds
- — 4 roles undisclosed
- New companies
- 4 First participation on record · 0 follow-on
- Funding in participating rounds
- $549.8M 4 disclosed · full round size, not this investor’s share
By stage
By primary sector
By country
Rounds
4 in this selectionTenpoint Therapeutics
Develops treatments to rejuvenate vision in the aging eye
$235MSeries B
Role not disclosedExciva
Develops novel therapies for behavioral symptoms associated with Alzheimer's Disease
€51MSeries B
Role not disclosedKinaset Therapeutics
Develops inhaled therapies for severe respiratory diseases
$103MSeries B
Role not disclosed